IE
PLRX icon

Israel Englander’s Pliant Therapeutics PLRX Stock Holding History

Israel Englander’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-16,800
Closed -$304K – 6454
2023
Q2 		$304K Buy
+16,800
New +$398K ﹤0.01% 4877

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Israel Englander's PLRX Position: Q2 2026 in Review

Israel Englander reduced its Pliant Therapeutics (PLRX) stake by 53% in Q2 2026, selling an estimated $756K and leaving 559,447 shares worth $638K. The position accounts for ﹤0.01% of the portfolio, ranked #4610.

Israel Englander first reported a position in PLRX in Q2 2020 and has held it in 22 quarters since. The position peaked at $9.89M in Q1 2023. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

  • Israel Englander held 559,447 shares of Pliant Therapeutics worth $638K as of Q2 2026.
  • Israel Englander sold 621,071 Pliant Therapeutics shares in Q2 2026, an estimated $756K.
  • Pliant Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #4610 holding.
  • Israel Englander first reported a position in Pliant Therapeutics in Q2 2020 and has held it in 22 quarters since.
  • Israel Englander's Pliant Therapeutics position peaked at $9.89M in Q1 2023.
  • 86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.